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Abstract
Under the global health emergency caused by coronavirus disease 2019 (COVID-19), efficient and spe-
cific therapies are urgently needed. Compared with traditional small-molecular drugs, antibody therapies
are relatively easy to develop and as specific as vaccines in targeting severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), and thus attract much attention in the past few months. This work reviews
seven existing antibodies for SARS-CoV-2 spike (S) protein with three-dimensional (3D) structures de-
posited in the Protein Data Bank. Five antibody structures associated with SARS-CoV are evaluated for
their potential in neutralizing SARS-CoV-2. The interactions of these antibodies with the S protein receptor-
binding domain (RBD) are compared with those of angiotensin-converting enzyme 2 (ACE2) and RBD
complexes. Due to the orders of magnitude in the discrepancies of experimental binding affinities, we
introduce topological data analysis (TDA), a variety of network models, and deep learning to analyze the
binding strength and therapeutic potential of the aforementioned fourteen antibody-antigen complexes.
The current COVID-19 antibody clinical trials, which are not limited to the S protein target, are also re-
viewed.
Key words: COVID-19, SARS-CoV-2, antibody therapy, binding affinity, persistent homology, deep learn-
ing, network analysis.
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Introduction
Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has rapidly spread around the world. By June 17, 2020, more than 8.2 million individuals
were infected and 443,000 fatalities had been reported. Currently, there are neither specific drugs nor effec-
tive vaccines available [7]. Traditional drug discovery involves a long and costly process, requiring more
than 10 years to put an average drug on the market. Vaccine development typically takes more than one
year. In contrast, developing potent SARS-CoV-2 specified antibodies that are produced from blood B cells
in response to and counteracting SARS-CoV-2 antigens is a less time-consuming and more efficient strategy
for combating the ongoing pandemic [7, 29, 34, 47, 54, 62, 70, 71, 78, 82, 85].
Antibody (Ab), also called immunoglobulin (Ig), is a large, Y-shaped protein that typically consists of
two identical heavy chains and two identical light chains. A heavy chain can be separated into two regions,
the constant region and the variable region. Moreover, each light chain has two successive domains, the
constant domain and the variable domain. The two heavy and two light chains of an antibody are connected
through disulfide bonds within the constant region [50]. An antibody binds the antigenic determinant (also
called epitope) through the variable regions in the tips of the heavy and light chains. Each of these chains
contains three complementarity determining regions (CDRs), which located in the tips of each variable
domain. Most of the diversities between antibodies are generated within the CDRs, which determine the
specificity of individuals of antibodies.
Benefit from the broad specificity of antibodies; antibody therapies have been proven to be a promising
way to fight against cancer, autoimmune disease, neurological disorders, and infectious viruses such as
HIV, Ebola, and Middle Eastern respiratory syndrome (MERS) [10, 56, 73]. Recently, several studies have
shown that the convalescent plasma of SARS-CoV-2 patients, which contains neutralizing antibodies cre-
ated by the adaptive immune response, can effectively improve patient survival rate [6, 8, 57]. However,
plasma-based therapeutics cannot be produced on a large scale. Therefore, seeking potent industrial-scale
antibody therapies becomes one of the most feasible strategies to fight against SARS-CoV-2. The spike (S)
protein, a multi-functional molecular machine that binds the human cell receptor angiotensin-converting
enzyme 2 (ACE2), has been taking as the target of neutralizing antibodies and the focus of therapeutic and
vaccine design efforts [64]. Many researchers have reported the binding affinities of SARS-CoV-2 S protein
in complex with antibody candidates and ACE2. However, these reported values may vary by two orders
of magnitude for a given antibody due to different experimental methods, conditions, calibrations, and hu-
man errors, which hinders the development of antibody therapies for SARS-CoV-2. Therefore, developing
a unified paradigm for ranking the potency of SARS-CoV-2 antibodies is a pressing need.
In this work, we review seven existing SARS-CoV-2 antibody therapeutic candidates in the literature.
As molecular structures are able to reveal the molecular mechanism of antibody-antigen interactions, we
only focus on the SARS-CoV-2 S protein antibodies that have three-dimensional (3D) structures released
on the Protein Data Bank (PDB). Since antibodies may directly compete with ACE2 for binding to the S
protein receptor-binding domain (RBD), the structure and binding affinity of ACE2 and S protein com-
plexes are studied to understand the efficiency of antibodies. Moreover, since the S proteins of SARS-CoV
and SARS-CoV-2 share 80% amino acid sequence identity [67], SARS-CoV S protein antibodies potential
candidates for COVID-19. Therefore, we review five existing SARS-CoV S protein antibodies and analyze
their binding affinities with the SARS-CoV-2 S protein. Furthermore, we employ topological data analysis
(TDA), artificial intelligence (AI), and a variety of network models to address literature controversy and
provide a unified paradigm for ranking the potency of all antibodies. Finally, we review the clinical trials
of COVID-19 antibody candidates.
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1 An overview of antibody structures, functions, and therapies
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Figure 1: A schematic illustration of antibody.
An antibody can be divided into different parts according to its functions. Specifically, the “arms” of the
Y-shaped protein contain sites that can recognize and bind to specific antigens. This region of the antibody
is called a Fab (fragment, antigen-binding) region and composed of one constant domain and one variable
domain from each heavy (VL) and light chain (VH) of the antibody [50]. Figure 1 illustrates the structure
of the antibody. The variable domain (Fv region) is the most important region for binding to antigens. To
be specific, on light and heavy chains, complementarity-determining regions (CDRs) composed of three
variable loops of β-strands are responsible for binding to a specific antigen. The CDRs are incredibly vari-
able, allowing a large number of antibodies with slightly different tip structures, or antigen-binding sites,
to exist. Each of these variants can bind to a different antigen so that the enormous diversity of antibody
paratopes on the antigen-binding fragments allows the immune system to recognize an equally wide va-
riety of antigens [41]. This antibody paratope diversity is generated by random recombination events of a
set of gene segments that encode different antigen-binding sites (or paratopes), followed by random muta-
tions in this area of the antibody gene to create further diversity [14,40]. It has been estimated that humans
generate about 10 billion different antibodies [22]. The base of the Y plays a role in modulating immune cell
activity. This region is named an Fc (Fragment, crystallizable) region and is composed of two heavy chains.
The Fc region ensures each antibody generates an appropriate immune response for a given antigen, by
binding to a specific class of Fc receptors or other immune molecules. This process activates different phys-
iological effects, including recognition of opsonized particles, lysis of cells, and degranulation of mast cells,
basophils, and eosinophils [31, 77].
In addition to conventional antibodies, camelids also produce heavy-chain-only antibodies (HCAbs).
HCAbs, also referred to as VHHs, or nanobodies, contain a single variable domain (VHH) that makes up the
equivalent antigen-binding fragment (Fab) of conventional immunoglobulin G (IgG) antibodies [27]. This
single variable domain typically can acquire affinity and specificity for antigens comparable to conventional
antibodies. VHHs can easily be constructed into multivalent formats and have higher thermal stability and
chemostability than most antibodies do [12, 15, 25, 38, 55, 65]. Another advantage of VHHs is that they are
less susceptible to steric hindrances than larger conventional antibodies [23].
In immune systems, antibodies are generated and secreted by B cells, mostly differentiated B cells, in-
cluding plasma cells or memory B cells. Antibodies have two physical forms, a membrane-bound form
called the B-cell receptor (BCR), which is found to attach to the surface of B cells, and a soluble form that
moves freely in the blood plasma. The BCR facilitates the activation and subsequent differentiation of B cells
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into either plasma or memory B cells. The activation of B cells has two mechanisms: T cell-dependent (TD)
activation and T cell-independent (TI) activation [42]. In the TD activation, once a BCR binds a TD antigen,
the antigen is taken up into the B cell through receptor-mediated endocytosis, degraded, and presented
to T helper (TH) cells as peptide pieces in complex with major histocompatibility complex-II (MHC-II)
molecules on the cell membrane [1]. TH cells recognize and bind these MHC-II-peptide complexes through
their T cell receptor (TCR). Following TCR-MHC-II-peptide binding, T cells express the surface protein
CD40L as well as cytokines such as IL-4 and IL-21. These signals promote B cell proliferation, immunoglob-
ulin class switching, somatic hypermutation, and guide differentiation. Once receiving these signals, B cells
are activated [11]. In the TI activation, T cells are absent and B cells receive signals from recognition and
binding of a common microbial constituent to toll-like receptors (TLRs) or extensive crosslinking of BCRs
to repeated epitopes on a bacterial cell [42]. The TI activation is rapid, but antibodies generated from it tend
to have a lower affinity and are also less functionally versatile than those from TD activation [42]. After ac-
tivated, B cells can be differentiated into plasma cells or memory B cells to generate and secrete antibodies.
Memory B cells can even survive in a human body for years to remember the same antigen and trigger a
fast response upon future exposure [3].
Antibodies protect our health in four ways: first, their Fab regions can bind to pathogens, so that prevent
pathogens from entering or damaging cells; second, they trigger the removal of pathogens by macrophages
and other cells by coating the pathogen; third, they stimulate the destruction of pathogens by stimulating
other immune responses such as the complement pathway [51]; at last, antibodies can also lead to vasoac-
tive amine degranulation against certain types of antigens such as helminths and allergens [31].
The antibody mechanism enlightens the development of vaccines and antibody therapies. A vaccine
is typically made of weakened or killed forms of the microbe, its toxins, or one of its surface proteins that
resemble a disease-causing microorganism. These forms cannot cause an infection, but the immune system
still regards them as a foreign object and produces antibodies in response. After the threat has passed, most
of the antibodies will break down, but memory B cells remain and remember the antigens in the vaccine.
Antibody therapies were developed in the 1970s, following the discovery of the structures of antibodies
and the development of hybridoma technology, which provided the first reliable source of monoclonal
antibodies (mAbs) [4, 36]. Rather than extracted from convalescent patient plasma, mAbs are made from
identical immune cells that are all clones of a unique parent cell so that they can have a monovalent affinity
to the same epitope. As a result, the most significant advantage of mAbs over conventional small-molecular
drugs is their high specificity, which facilitates precise action [30]. The second advantage is their long
half-lives, which allows infrequent dosing [39]. Third, molecular engineering technologies have enabled
the structure of mAbs to be fine-tuned for specific therapeutic actions and to minimize immunogenicity
[26, 44, 49, 66], thus enhancing their safety. This is reflected in mAbs having an approval rate of around
20% compared with 5% for new small-molecular entities [52, 53]. Finally, mAbs can be developed in a
short time period, such as 5-6 months [35]. Currently, mAbs have already established their therapeutic and
prophylactic efficacy against cancer, autoimmune disease, neurological disorders, and infectious viruses
such as HIV, Ebola, and Middle Eastern respiratory syndrome (MERS) [10,56,73]. However, adverse effects
are mostly relating to immunomodulation and infection can be associated with therapeutic mAbs [30], such
as antibody-dependent enhancement [63] and cytokine storm [9].
2 SARS-CoV-2 antibody therapeutic candidates
Both SARS-CoV and SARS-CoV-2 belong to lineage B of the betacoronavirus genus and have four structural
proteins, known as spike, envelope, membrane, and nucleocapsid proteins [81, 86]. The nucleocapsid pro-
tein holds the RNA genome. Together with membrane, spike, envelope, and membrane proteins create the
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viral envelope [80]. Among them, the S protein that forms homotrimers protruding from the viral surface
mediates the entry of coronaviruses into host cells when binds with ACE2 [64]. More specifically, the S
protein comprises two functional subunits: the S1 that is responsible for binding to the host cell receptor
and the S2 that promotes the fusion of the virus and cellular membranes [68, 69].
ACE2 is a single-pass transmembrane protein with its active domain exposed on the cell surface and is
expressed in the lungs and other tissues [28]. ACE2 serves as the main cell entry point for SARS-CoV and
SARS-CoV-2, and some other coronaviruses [70]. Notably, the equilibrium dissociation constant (Kd) of the
binding between ACE2 and S protein has significantly increased from SARS-CoV to SARS-CoV-2 [62, 67].
Moreover, plus SARS-CoV-2 may also use basigin to assist in cell entry [72]. Therefore, SARS-CoV-2 is more
infectious than SARS-CoV.
Antibody therapy is promising to fight against COVID-19. Figure 2 is a schematic illustration of anti-
body therapy for COVID-19. Notably, neutralizing monoclonal antibodies (mAbs) isolated from convales-
cent patient memory B cells provide effective intervention to SARS-CoV-2 due to their safety, scalability, and
therapeutic effectiveness [6, 8, 57]. As S protein mediates the host cell entry, it is the target of neutralizing
antibodies and the focus of therapeutic and vaccine design efforts [64].
Figure 2: A schematic illustration of antibody therapy.
Table 1 provides a summary of SARS-CoV-2 and SARS-CoV S protein RBDs in complexes with existing
antibodies and ACE2 structures. The structures, functions, and properties of these complexes are analyzed
below.
As summarized in Table 1, twelve mAbs targeting the SARS-CoV-2 or SARS-CoV S-protein RBD are
reported with their 3D experimental complex structures available in the Protein Data Bank. According to
the literature reports, the most promising one is S309 [47], which shows almost equally neutralization po-
tency against both SARS-CoV and SARS-CoV-2. The authors state that 19 out of 24 residues of the S309’s
epitope are strictly unchanged from SARS-CoV and SARS-CoV-2, and the other 5 residues are conserva-
tively or semi-conservatively substituted [47]. However, some other researchers are still concerned about
the claimed cross-effectiveness against both SARS-CoV and SARS-CoV-2 [71]. Notably, two experimental
structures of the S309 and SARS-CoV-2 S-protein complex are released with closed and open conformations
of the S-protein, respectively. The binding affinity of S309 and S protein RBD complex is not sensitive to S
protein close or open conformations [47].
CR3022 is another potent antibody that may bind to both SARS-CoV and SARS-CoV-2 [62, 85]. It is
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Table 1: A summary of monoclonal antibodies targeting the SARS-CoV-2 or SARS-CoV S-protein with the 3D exper-
imental structures of their complexes available in Protein Data Bank. BLI: Biolayer interferometry, and SPR: Surface
plasmon resonance.
Protein or Antibody Target Kd (nM) / Method PDBID Resolution (A˚)
1.2 / BLI [67]
ACE2 SARS-CoV-2 RBD 34.6 / BLI [79] 6M0J [37] 2.45
15.2 / BLI [62]
S309 SARS-CoV-2 RBD IgG=0.104 Fab=1.98 / BLI [47] 6WPS, 6WPT [47] 3.10, 3.70
CR3022 SARS-CoV-2 RBD IgG=6.28 / BLI [62] 6W41 [85] 3.08
IgG<0.1 Fab=115 / BLI [85]
CB6 SARS-CoV-2 RBD IgG=2.49 / SPR [58] 7C01 2.85
P2B-2F6 SARS-CoV-2 RBD IgG=5.14 / SPR [34] 7BWJ [34] 2.85
B38 SARS-CoV-2 RBD IgG=70.1 / SPR [82] 7BZ5 [82] 1.84
H11-D4 SARS-CoV-2 RBD 6Z43 3.30
BD23 SARS-CoV-2 RBD 7BYR [7] 3.84
5.0 / BLI [67]
ACE2 SARS-CoV RBD 325.8 / BLI [79] 3D0G 2.80
1.70 / BLI [59]
CR3022 SARS-CoV RBD IgG<0.1 Fab=1 / BLI [85]
S309 SARS-CoV RBD IgG=0.12 Fab=1.81 / BLI [47]
m396 SARS-CoV RBD IgG=0.005 Fab=20 / BLI [48] 2DD8 [48] 2.30
S230 SARS-CoV RBD IgG=0.06 / BLI [70] 6NB6 [70] 4.30
VHH-721 SARS-CoV RBD IgG=1.15 / SPR [78] 6WAQ [78] 2.20
80R SARS-CoV RBD IgG=1.59 / BLI [59] 2GHW [32] 2.30
F26G19 SARS-CoV RBD Fab=26 / SPR [45] 3BGF [45] 3.00
also showed that compared with m396, a SARS-CoVspecific antibody, CR3022 has a significantly stronger
binding signal to SARS-CoV-2. However, this affinity to SARS-CoV-2 is much weaker than the affinity to
SARS-CoV [85]. It is also suggested that CR3022 can only access to the open conformation of the S-protein
RBD [85].
CB6 and P2B-2F6 are also promising SARS-CoV-2 antibodies, which are specific human mAbs extracted
from convalescent COVID-19 patients [34, 58]. VHH-72 cross-reacts with SARS-CoV-2 and SARS-CoV S-
proteins, but the affinity to SARS-CoV-2 is much lower than SARS-CoV [78]. B38 also shows a direct com-
petition with ACE2 for binding to SARS-CoV-2 S-protein [82].
2.1 3D structure alignment
All the available 3D structures of SARS-CoV-2 S protein RBD in complex of the antibodies are aligned to
ACE2. Figures 3 and 4 show the alignment of SARS-CoV-2 and SARS-CoV antibodies, respectively. The
PDB ID of these complexes can be found in Table 1.
As revealed in Figure 3, the antibodies CB6, B38, H11-D4, and P2B-2F6 have their epitopes overlapping
with the ACE2 binding site, suggesting their bindings are in direct competition with that of ACE2. Theoret-
ically, this direct competition reduces the viral infection rate. For an antibody with strong binding ability, it
will directly neutralize SARS-CoV-2 without the need of antibody-dependent cell cytotoxicity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP) mechanisms. However, the binding sites of epitopes
of S309 and CR3022 are away from that of ACE2, leading to the absence of binding competition [47, 62].
1The binding affinity of VHH-72 with SARS-CoV-2 RBD is Fab= 54 nM.
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Figure 3: The alignment of the available 3D structures of SARS-CoV-2 S-protein RBD in binding complexes with antibodies as well as
ACE2.
One study shows the ADCC and ADCP mechanisms contribute to the viral control conducted by S309
in infected individuals [47]. For CR3022, researches indicate that it neutralizes the virus in a synergistic
fashion [60].
Figure 3 shows that on the SARS-CoV RBD, antibodies S230, 80R, F26G19, and m396 have their epi-
topes overlapping with ACE2. VHH-72 locates slightly away from the ACE2 binding site but still sterically
clashes with the ACE2 binding. They all lead to binding-competitions to naturalize the virus.
2.2 Alignment of antibody and ACE2 epitopes on S protein two-dimensional (2D)
sequences
Figure 5 highlights the contact regions of antibody and ACE2 epitopes on SARS-CoV-2 RBD or SARS-CoV
RBD 2D sequences. Consistent with the 3D alignment, except for S309, CR3022, and VHH-72, all the other
antibodies have their epitopes overlapping with the ACE2 binding site, especially the residues from 486 to
505 of the SARS-CoV-2 RBD (corresponding to the residues 472 to 491 of the SARS-CoV RBD). Although the
VHH-72 epitope residues do not overlap with the ACE2 binding site, VHH72 occupies parts of the space
of the ACE2 binding site, which will disrupt the ACE2 binding with RBD. Therefore, VHH-72 also has
a competitive binding ability against ACE2. Figure 5 also reveals that these epitope residues have many
mutations from SARS-CoV-2 RBD to SARS-CoV RBD, which could explain why most of the antibodies lack
cross-reaction to both SARS-CoV-2 and SARS-CoV. This aspect will be further studied in a later section.
3 Experimental pitfalls in the affinity measurements of antibody bind-
ing with S protein RBD
Table 1 clearly displays the discrepancy in reported experimental Kd values for ACE2 in complexes with
SARS-CoV-2 S-protein (i.e., 1.2 nM [67], 15.2 nM [62], and 34.6 nM [79]). Moreover, a 191-fold difference in
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Figure 4: The alignment of the available 3D structures of SARS-CoV S-protein RBD in binding complexes with antibodies as well as
ACE2.
magnitude has been reported in experimental Kd values for ACE2 and SARS-CoV S-protein complex (i.e.,
5.0 nM [67], 325.8 nM [79], and 1.70 nM [59]).
The inconsistency mentioned above in experimental values is not isolated. The experimental Kd values
for CR3022 binding with the SARS-CoV-2 S protein RBD were reported as 6.28 nM [62] and <0.1 nM [85].
This level of discrepancy in reported experimental values makes it impossible to select antibody candidates
appropriately.
As shown in Table 1, two binding assay techniques are used to measure Kd values of antibody-antigen
interactions. The discrepancies in Kd values for CR3022 discussed above are based on biolayer interfer-
ometry (BLI) measurements. BLI detects the surface changes on biosensor tips induced by protein-protein
association and dissociation by using analyzing the interference pattern of white light reflected from the
surface. BLI results are sensitive to biosensor preparation, the stability of the light source, the temperature
control, and the calibration. Surface plasmon resonance (SPR) has been employed for determining the Kd
values of antibody and RBD complexes as shown in Table 1. This method detected the reflectivity changed
induced by molecular adsorption, such as polymers, DNA or proteins, etc. by changes in reflection angles.
Similarly, SPR is also sensitive to the preparation of conjugated antigens, the stability of the light source,
the temperature control, and the calibration. The widespread inconsistency in reported antibody and S
protein binding affinities motivates us to carry out computational analysis of existing antibody-S protein
complexes described below.
4 Computational analysis of antibody-SARS-CoV-2 interactions
To have unified assessment and ranking of S protein RBD binding complexes with antibodies and ACE2,
we utilize topological data analysis, graph theory, network models, and machine learning to analyze the
3D complexes presented in Table 1. We also evaluate the re-purposing potentials of SARS-CoV antibodies
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Figure 5: Illustration of the contact positions of antibody and ACE2 epitope with SARS-CoV-2 and SARS-CoV S protein RBDs on
RBD two-dimensional (2D) sequences. The proteins in the structures of 6M0J, 6WPS, 6W41, 7C01, 7BWJ, 7BZ5, 6Z43, and 7BYR are in
complexes with SARS-CoV-2 S-protein while the proteins in structures 3D0G, 2DD8, 6NB6, 6WAQ, 2GHW, and 3BGF are in complexes
with SARS-CoV S protein.
for SARS-CoV-2 using the TopNetTree model [74].
4.1 Ranking of ACE2 and antibodies
The prediction results and network descriptors are presented in Table 2 and Table 3 for SARS-CoV-2 com-
plexes and SARS1 complexes, respectively. In Table 2, the complexes are ranked according to their predicted
binding affinities, ∆G, followed by FRI rigidity indexes [43, 83] which have the highest covariance. They
are computed based on all the Cα atoms on the RBD and all the Cα atoms in antibodies or ACE2. The
FRI rigidity index Rη indicates the measurement of geometric compactness and topological connectivity of
protein-protein interactions at each residue, such that more impact of the longer pairwise interactions for
larger η. Comparing with the predicted energy, a strong binding affinity is corresponding to a large rigidity
index. Then the summation of binding affinity changes computed with the TopNetTree model [74] by mod-
ifying the RBD residues to glycine (G) are presented while S10 and S8 stand for those residues within 10A˚
and 8A˚ to the binding site are included. Each mutation to glycine (G) is calculated by PPI machine learning
model [74], where a positive binding affinity changes ∆∆G means a stronger binding affinity of mutant
and vice versa. Therefore, a summation of considered residues in the RBD with smaller values indicates a
strong binding affinity of wild type.
The rest of the table gives the Cα-based complex analysis from a number of network descriptors, in-
cluding edge density (d), degree heterogeneity (ρ) [17], average path length (〈L〉) [76], average betweenness
centrality (〈Cb〉) [24], average eigencentrality (〈Ce〉) [2], average subgraph centrality (〈Cs〉) [21], and net-
work communicability (〈M〉) [19]. Except for the degree heterogeneity which is calculated based only on
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Table 2: The graph network descriptor consisting of SARS-CoV-2 Spike protein RBD and ACE2 and antibodies. ∆G: the predicted
binding affinity (kcal/mol) (the predictions are using the Prodigy web server [84]); R10 and R8: FRI rigidity index with η of 10 and 8,
respectively; S10 and S8: the summation of binding affinity changes (∆∆G kcal/mol) by changing RBD residues within 10A˚ and 8A˚
to the binding site to glycine; d: edge density; ρ: degree heterogeneity; 〈L〉: average path length; 〈Cb〉: average betweenness centrality;
〈Ce〉: average eigencentrality; 〈Cs〉: average subgraph centrality; 〈M〉: network communicability.
Molecule CR3022 B38 CB6 ACE2 BD23 H11-D4 S309 P2B-2F6
PDB ID 6W41 7BZ5 7C01 6M0J 7BYR 6Z43 6WPS 7BWJ
∆G -15.4 -14.7 -13.5 -11.9 -10.8 -10.3 -9.9 -9.6
R10 335 349 338 279 227 201 256 211
R8 134 138 132 105 106 82 97 82
S10 19.15 30.17 36.56 20.83 10.39 8.91 18.28 17.74
S8 11.69 12.39 13.36 16.60 5.49 4.41 7.04 5.97
d 0.070 0.069 0.072 0.072 0.069 0.077 0.071 0.074
ρ 0.0192 0.0190 0.0196 0.0185 0.0171 0.0190 0.0206 0.0196
〈L〉 13.69 14.26 13.75 13.85 14.80 13.59 13.86 13.98
〈Cb〉 0.0109 0.0111 0.0110 0.0113 0.0130 0.0113 0.0112 0.0117
〈Ce〉 0.052 0.050 0.052 0.051 0.053 0.054 0.054 0.053
〈Cs〉 1590955 2397825 2010826 2105421 813061 2248985 1387110 1562243
〈M〉 847509 1237464 1096771 1132331 413572 1239452 753625 855641
〈Θ〉 0.0192 0.0190 0.0196 0.0185 0.0171 0.0190 0.0206 0.0196
the RBD Cα atoms, other descriptors are calculated from all Cα atoms on the RBD and antibody (or ACE2)
Cα atoms within 10A˚ from any Cα atom on the RBD. The degree heterogeneity demonstrates antibody or
ACE2 influence to the RBD, such that close degree heterogeneity numbers would have similar impacts.
For example, molecules B38 and H11-D4 have degree heterogeneity values that are close to ACE2 as well
as sharing the same receipt domain. As for other descriptors, the average betweenness centrality [24] and
average eigencentrality [2] values are correlated quite well to the predicted binding affinities.
Table 3 shows the results of predictions and network descriptors for the SARS-CoV S protein complex.
Again, the predicted binding affinities have high correlations to FRI rigidity indexes. For degree hetero-
geneity, m396 has a similar impact as ACE2. In Table 3, molecule 80R (PDB 2GHW) has the highest rigidity
index both for η = 10 and η = 8 which indicates a more rigid complex structure between 80R and the RBD.
In the comparison of SARS-CoV S protein RBD and SARS-CoV-2 S protein RBD in Table 2, descriptors are
close to each other except for the summation of binding affinity changes which includes more biological
and chemical information than others. Thus, the network structures for SARS-CoV RBD and SARS-CoV-2
RBD complex are similar.
4.2 Prediction of binding affinity changes following mutations
In this section, we predict the binding affinities of SARS-CoV antibodies when they are applied to SARS-
CoV-2 neutralization. Specifically, we compute the binding affinity changes following the mutations from
SARS-CoV RBD to SARS-CoV-2 RBD. These changes can be very significant. Study shows that a single
mutation (V367F) can lead to a 10-fold increase in IC50 for a particular antibody [54].
In Figure 6, the blue bars are predicted binding affinities of each SARS-CoV-2 complex, and the red bars
are predicted binding affinities of each molecule with SARS-CoV-2 RBD, which is calculated by accumulat-
ing binding affinities of single mutations from SARS-CoV RBD to SARS-CoV-2 RBD and adding the sum
to the binding affinities of SARS-CoV complexes. Obviously, molecule 80R (PDB: 2GHW) has the largest
binding energy change in SARS-CoV ranking as well as in SARS-CoV-2 ranking among these SARS-CoV
antibodies. Molecule VHH-72 (6WAQ) had a smaller binding affinity than ACE2(3D0G) does for SARS-CoV
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Table 3: The graph network descriptor consisting of SARS-CoV Spike protein RBD and ACE2 and antibodies. ∆G: the predicted
binding affinity (kcal/mol) (the predictions are using the Prodigy web server [84]); R10 and R8: FRI rigidity index with η of 10 and 8,
respectively; S10 and S8: the summation of binding affinity changes (∆∆G kcal/mol) by changing RBD residues within 10A˚ and 8A˚
to the binding site to glycine; d: edge density; ρ: degree heterogeneity; 〈L〉: average path length; 〈Cb〉: average betweenness centrality;
〈Ce〉: average eigencentrality; 〈Cs〉: average subgraph centrality; 〈M〉: network communicability.
Molecule 80R ACE2 VHH-72 m396 S230 F26G19
PDB ID 2GHW 3D0G 6WAQ 2DD8 6NB6 3BGF
∆G -17.3 -11.5 -9.7 -9.4 -7.7 -6.7
R10 378 270 255 304 195 254
R8 157 101 103 119 72 101
S10 20.35 13.05 13.37 10.79 11.48 14.01
S8 8.92 1.56 7.49 6.47 8.09 7.84
d 0.070 0.070 0.074 0.073 0.078 0.072
ρ 0.0206 0.0187 0.0193 0.0186 0.0197 0.0190
〈L〉 13.35 12.91 13.46 12.90 12.96 12.63
〈Cb〉 0.0120 0.0108 0.0109 0.0113 0.0119 0.0113
〈Ce〉 0.053 0.053 0.053 0.054 0.054 0.056
〈Cs〉 2693776 1418662 1607217 2383597 3167175 1897873
〈M〉 1446506 730809 915061 1311299 1714397 1039376
〈Θ〉 0.0206 0.0187 0.0192 0.0186 0.0196 0.0190
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Figure 6: An illustration of the binding affinities of antibodies with SARS-CoV and SARS-CoV-2 RBD. Molecular names of these
antibodies are 80R (PDB: 2GHW), ACE2 (3D0G), VHH-72 (6WAQ), m396 (2DD8), S230 (6NB6), and F26G19 (3BGF).
RBD while an equivalent binding affinity for SARS-CoV-2 RBD. Molecules m396, S230, and F26G19 have
weaker binding affinities after modifying from SARS-CoV RBD to SARS-CoV-2 RBD. Finally, the binding
affinity of SARS-CoV RBD with ACE2 following mutations to SARS-CoV-2 is slightly higher than the bind-
ing affinity of SARS-CoV RBD with ACE2, indicating that SARS-CoV-2 is more infectious than SARS-CoV.
This is consistent with experimental reports [67, 79].
Figures 7 and 8 show the binding affinity changes on individual mutations on the SARS-CoV S protein
RBD, where more precise trends can be observed. In Figure 7, molecule, 80R, has a similar trend to ACE2
which shares the most receipting domain. In Figure 8, most of the binding affinity changes following
mutations in receptor binding motif (RBM) of ACE2 are negative, which indicates stronger binding affinities
with SARS-CoV RBD.
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Figure 7: Overall binding affinity changes on the S protein receptor-binding domain (RBD) from SARS-CoV to SARS-CoV-2 of
molecules 80R, ACE2, and VHH-72. The x-axis records the wild type to the mutate type at the specific residue position. The pink
color region marks the receptor-binding motif (RBM) corresponding to ACE2. The height of each bar indicates the predicted binding
affinity changes. A positive change indicates a strengthening in binding.
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Figure 8: Overall binding affinity changes on the S protein receptor-binding domain (RBD) from SARS-CoV to SARS-CoV-2 of
molecules m396, S320, and F26G19. The x-axis records the wild type to the mutate type at the specific residue position. The pink
color region marks the receptor-binding motif (RBM) corresponding to ACE2. The height of each bar indicates the predicted binding
affinity changes. A positive change indicates a strengthening in binding.
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4.3 Network analysis of antibody-antigen complexes
Various network models have been employed to analyze the structure and function of SRAS-CoV and
SASR-CoV-2 main protease [18]. In this work, we utilize network models to illustrate interactions between
the binding complexes of the RBD of SARS-CoV or SRAS-CoV-2 and antibodies or ACE2.
In the microscopy of each single residue, their performances on network models reveal the similarities
and differences between complexes. In Figure 9, SARS-CoV RBD with ACE2 (PDB: 3D0G), SARS-CoV-2
RBD with ACE2 (PDB: 6M0J), and SARS-CoV-2 RBD with CR3022 (PDB: 6W41) are listed and aligned where
6W41 has the strongest predicted binding affinity and the largest deviation to 6M0J as shown in Tables 2
and 3. The Cα atoms from the RBD are marked as a circle, and atoms from ACE2 or CR3022 are marked as a
cube. In the first row of Figure 9, it is interesting to observe all three complexes having similar domains that
have high rigidity index values. In the comparison of betweenness centralities of three structures, though it
is shown clearly that 3D0G has many large values, it has the lowest average betweenness centrality among
the structures as shown in Tables 2 and 3. Analogy to the rigidity index, all three complexes have the same
regions of the individual eigencentrality values and subgraph centrality values. Overall, the differences
between 3D0G and 6M0J are quite close in their network analysis. However, the betweenness centrality
reflects their difference such that a higher average value would indicate a stronger binding affinity. More-
over, all three complexes coincidentally have similar regions of high values for network descriptors, which
suggests that this region would play a key role in protein-protein interactions.
5 Clinical trials of COVID-19 antibody therapeutic candidates
Table 4 summarizes the currently ongoing clinical trials of COVID-19 antibody therapeutic candidates in
the United States, China and Europe. These data are collected from the National Institutes of Health (NIH)
(https://www.nih.gov/coronavirus), the European Medicines Agency (EMA) (https://www.clinicaltrials
register.eu/ctr-search/search?query=covid-19), and the media’s reports.
Notably, most of the current COVID-19 antibody therapeutic candidates in clinical trials are aimed at
other targets rather than the S protein. These antibodies were developed for other diseases initially and
now repurposed to treat COVID-19, which could alleviate some COVID-19 symptoms such as cytokine
storm and inflammation instead of killing the viruses.
Nonetheless, two antibody candidates under clinical trials are targeting at S protein and block the SARS-
CoV-2 entry into human cells. One is LY3819253 developed by Eli Lilly and Company in the United States,
which is in phase II clinical trial and already highlighted in TheScientist (https://www.the-scientist.com/n
ews-opinion/first-antibody-trial-launched-in-COVID-19-patients--67604). The other is JS016 performed
by Junshi Biosciences in China [58], which is currently in phase I clinical trial.
Table 4: The summary of current on-going clinical trials of Covid-19 antibody therapeutic candidates.
2
Antibody ID Manufacturer Target Trial location Trial Start
phase date
Lanadelumaba Shire pKal Radboud University
Medical Center,
Nijmegen, Netherlands
4 /
Octagama Pfizer Antibody
mixture
Sharp Memorial
Hospital, San Diego,
California, United States
4 4.28.2020
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Sarilumaba,b Regeneron
Pharmaceuticals
and Sanofi
IL-6 Assistance Publique -
Hpitaux de Paris, Paris,
France;
3 3.25.2020
VA Boston Healthcare
System,Boston,
Massachusetts, United
States
2 4.10.2020
Sirukumaba,b Janssen Biotech IL-6 Sanofi-aventis Recherche
et Dveloppement,
Chilly-Mazarin, France;
3 3.26.2020
Loyola University
Medical
Center,Maywood,
Illinois, United States
2 4.24.2020
Canakinumaba,b Novartis Interleukin-
1β
Novartis Investigative
Site, Glendale,
California,United States;
3 4.30.2020
Novartis Pharma GmbH,
Nrnberg, Germany
3 4.29.2020
IFX-1b InflaRx C5a InflaRx GmbH, Jena,
Germany
3 3.29.2020
Lenzilumaba Humanigen GM-CSF Mayo Clinic, Phoenix,
Arizona,United States
3 4.30.2020
Mylotargb Celltech and
Wyeth
CD33 UK Research and
Innovation,United
Kingdom
3 5.5.2020
Ravulizumabb Alexion C5 Alexion Europe SAS, 3 5.7.2020
Pharmaceuticals Levallois-Perret, France
Tocilizumaba,b Roche IL-6 Queen’s Medical Center,
Honolulu,Hawaii,United
States;
3 6.1.2020
F. Hoffmann-La Roche
Ltd, Basel, Switzerland
3 4.6.2020
Avdoralimabb Innate Pharma C5a Assistance Publique
Hopilaux De Marseille,
Marseille, France
2 4.23.2020
Bevacizumabb Genentech VEGF-A Fundacin para la
Investigacin Biomdica de
Crdoba, Crdoba, Spain
2 4.24.2020
CERC 002a Cerecor LIGHT Cape Fear Valley Medical
Center, Fayetteville,
North Carolina,United
States
2 6.9.2020
Clazakizumaba Bristol Myers
Squibb and Alder
Biopharmaceuti-
cals
IL-6 Cedars-Sinai Medical
Center,Los Angeles,
California, United States
2 4.24.2020
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Gimsilumaba Eisai Inc GM-CSF UCLA Ronald Reagan
Medical Center, Los
Angeles,
California,United States
2 4.12.2020
IC14a Scripps Research CD14 University of
Washington,
Seattle,Washington,
United States
2 7.2020
Infliximaba Janssen Biotech TNFα Tufts Medical
Center,Boston,
Massachusetts, United
States
2 6.1.2020
Leronlimaba CytoDyn CCR5 University of California,
Los Angeles, California,
United States
2 4.1.2020
LY3127804a Eli Lilly and
Company
Ang2 NorthShore University
HealthSystem, Evanston,
Illinois, United States
2 4.20.2020
LY3819253a Eli Lilly and
Company
S protein Cedars Sinai Medical
Center, Los Angeles,
California, United States
2 6.13.2020
Mavrilimumaba MedImmune GM-CSF Cleveland Clinic Health
System,Cleveland, Ohio,
United States
2 5.20.2020
MSTT1041Aa Genentech ST2 eStudySite-Chula
Vista-PPDS,Chula Vista,
California, United States
2 6.2.2020
Nivolumabb Bristol-Myers
Squibb
PD-1 Centre Lon Brard, Lon,
France
2 4.1.2020
Otilimaba,b MorphoSys GM-CSF GSK Investigational Site,
Saint Louis Park,
Minnesota, United States;
2 5.28.2020
GlaxoSmithKline
Research Development
Limited, Brentford,
United Kingdom
2 5.20,2020
Siltuximabb Eusapharma IL-6 Fundaci Clnic per a la
Recerca Biomdica,
Barcelona, Spain
2 4.7.2020
SNDX-6352a Syndax
Pharmaceuticals
CSF-1R HonorHealth,Scottsdale,
Arizona, United States
2 5.30.2020
ARGX-117b Argenx C2 Argenx BV, Zwijnaarde,
Belgium
1 4.21.2020
TJ003234a / GM-CSF GW Medical Faculty
Associates,Washington,
District of
Columbia,United States
1 4.11.2020
15
JS016c Junshi Biosciences S protein Huashan Hospital
Affiliated to Fudan
University, Shanghai,
China
1 6.7.2020
6 Material and methods
6.1 Sequences and structures
All the sequences and 3D structures are downloaded from Protein Data Bank ( https://www.rcsb.org): the
sequences are from the FASTA files, the 3D structures are from the pdb files.
The 3D alignments as well as the graphs are created by using PyMOL [13]. The 2D sequence alignment
are calculated by clustalw ( https://www.genome.jp/tools-bin/clustalw) [61], the 2D alignment graphs are
generated by Jalview [75].
6.2 TopNetTree model for protein-protein interaction (PPI) binding affinity changes
upon mutation
In this section, the topology-based network tree (TopNetTree) is presented, which predicts binding affinity
changes following mutation ∆∆G for PPIs [74]. This method is based on structures regarded as topo-
logical features and supervised machine learning model, gradient boosting tree (GBT), and convolution
neural network (CNN). In Fig. 10, the train and predicting process is elucidated that two major modules
are applied the topology-based feature generation and a CNN-assisted GBT model. In feature generation,
the element- and site-specific persistent homology is the key mathematical technique that can simplify the
structural complexity of protein-protein complexes and translate the biological information into topolog-
ical invariants. The first step of the TopNetTree process uses CNN as an assistant model to manipulate
the topological features. Assembling CNN-pretrained features and other features, the last step of the GBT
model predicts PPIs binding affinity changes. Other features such as chemical and physical information
that have not been absorbed into topological features can improve the proposed model’s predicting ability.
More details are referred to in the literature [74].
6.2.1 Topology-based feature generation of PPIs
Persistence homology is the key mathematical theory behind the topology-based feature generation. As
a subtopic of algebraic topology, persistence homology is built upon simplicial complex and filtration on
discrete datasets under various settings. For example, the set of atoms in protein-protein interactions forms
the discrete dataset. When building the constructions, a variety of simplicial complex built on point clouds
such that Vietoris-Rips (VR) complex and alpha complex are widely used [16] which are applied in our
2List of links of antibodies in Table 4:
a https://clinicaltrials.gov/ct2/results?recrs=ab&cond=covid-19&term=&cntry=US&state=&city=&dist=
b https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19
c https://www.globenewswire.com/news-release/2020/06/07/2044620/0/en/Junshi-Biosciences-Announces-Dosing-of-First-Hea
lthy-Volunteer-in-Phase-I-Clinical-Study-of-SARS-CoV-2-Neutralizing-Antibody-JS016-in-China.html
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Figure 9: Cα network analysis of three antibody-antigen complexes. Circle markers are for antigen (spike protein RBD) and cube
markers are for antibody or ACE2. Columns list complexes 3D0G, 6M0J, and 6W41. Rows represent FRI rigidity index, betweenness
centrality, eigencentrality, and subgraph centrality.
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Figure 10: An illustration of the TopNetTree model [74]. Protein structure shown in the plot is SARS-CoV-2 spike receptor-binding
domain bound with antibody (PDB 7BZ5). Here, H0 are the 0-dimensional topological input features for machine learning model.
approach. After a simplicial complex set up, the topological invariants of the point-cloud dataset can be
identified and are enumerated by counting the numbers referred to as Betti-0 (H0), Betti-1 (H1), and Betti-2
(H2) for components, rings, and cavities of dataset, respectively. Obviously, the complexity protein-protein
structure is simplified as its geometric and topological characteristics for data features, while redundant
and uninformative features or calculations are fully abandoned. Moreover, making filtration on simplicial
complex turns the 3D point-cloud dataset of PPIs into topological barcodes, which record the “birth” and
“death” of each topological invariants. The topological features simplify the PPI-complex in many direc-
tions. However, it is also essential to have better construction to reflect different biological or chemical
properties. Various subsets are defined as following for PPI complex constructions.
1. Am: atoms of the mutation sites.
2. Amn(r): atoms in the neighbourhood of the mutation site within a cut-off distance r.
3. AAb(r): antibody atoms within r of the binding site.
4. AAg(r): antigen atoms within r of the binding site.
5. Aele(E): atoms in the system that has atoms of element type E.
Therefore, the distance matrix is defined based on atom sets such that it excludes the interactions in the
same set. For interactions between atoms ai and aj in set A and/or set B, the modified distance is defined
as
Dmod(ai, aj) =
{
∞, if ai, aj ∈ A, or ai, aj ∈ B,
De(ai, aj), if ai ∈ A and aj ∈ B,
(1)
where De(ai, aj) is the Euclidian distance between ai and aj . Next, the persistence homology can be con-
structed element- and site-specific.
Given atomic coordinates, their topological analysis and properties can be carried out via simplices
and simplicial complexes. A set of k+1 affinely independent points, v0, v1, v2, ..., vk in Rn is a k-simplex
denoted σi, such that a 0-, 1-, 2-, or 3-simplex in geometry representation is a vertex, an edge, a triangle, or
a tetrahedron, respectively. The finite collection of simplex is a simplicial complex K = {σi}, which is true
if a subset (also called as face) τ of a k-simplex σi of K is also in K, τ ⊆ σi and σi ∈ K imply τ ∈ K and
the non-empty intersection of any two simplices in K is a face of both. Furthermore, a k-chain is a finite
formal sum of all simplices in K,
∑
i αiσ
k
i , where αi is coefficients in Zp and p is a chosen prime number.
The set of all k-chains of the simplicial complex K equipped with an algebraic field forms an abelian gourp
Ck(K,Zp).
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A boundary operator ∂k : Ck→Ck−1 for a k-simplex σk is homomorphism defined as
∂kσ
k =
k∑
i=0
(−1)i{v0, v1, · · · , vˆi, · · · , vk},
where {v0, v1, · · · , vˆi, · · · , vk} is a (k−1)-simplex excluding vi from the vertex set. An important property
of boundary operator, ∂k−1∂k = ∅, follows from that boundaries are boundaryless. Moreover the kernel
of boundary operator is Zk = ker∂k = {c ∈ Ck | ∂kc = ∅}, whose elements are called k-cycles; and the
kth boundary group is the image of ∂k+1 denoted as Bk = im ∂k+1 = {∂k+1c | c ∈ Ck+1}. The algebraic
construction to connect a sequence of complexes by boundary maps is called a chain complex
· · · ∂i+1−→ Ci(X) ∂i−→ Ci−1(X) ∂i−1−→ · · · ∂2−→ C1(X) ∂1−→ C0(X) ∂0−→ 0
and the kth homology group is the quotient group defined byHk = Zk/Bk. Obviously, boundary operators
imply Bk ⊆ Zk ⊆ Ck. The Betti numbers are defined by the number of basis in kth homology group Hk
which counts k-dimensional holes. For example, Betti 0, β0 = rank(H0) reflects the number of connected
components; Betti 1, β1 = rank(H1) reflects the number of loops; and Betti 2, β2 = rank(H2) reveals the
number of voids or cavities. Together, the set of Betti numbers {β0, β1, β2, · · · } indicates the intrinsic topo-
logical property of a system. Computational, boundary operators directly work on the distance matrices
generated on different atom groups, and the Betti number can be calculated by counting the number of zero
eigenvalues of corresponding boundary operators.
It is interested in the evolution of a simplicial complex and to track topological characteristics varying
as the simplicial complex changes. In persistent homology, a filtration of a topology space K is a nested
sequence of subspaces {Kt}t=0,...,m of K such that ∅ = K0 ⊆ K1 ⊆ K2 ⊆ · · · ⊆ Km = K. Considering
the complex group on this sequence, we can have a sequence of chain complexes by homomorphisms:
C∗(K0) → C∗(K1) → · · · → C∗(Km) and a corresponding homology sequence: H∗(K0) → H∗(K1) →
· · · → H∗(Km). The p-persistent kth homology group of Kt is defined as Ht,pk = Ztk/(Bt+pk
⋂
Ztk), where
Bt+pk = im∂k+1(K
t+p). Hence, the homology group reveals that the homology classes of Kt persist until
Kt+p. In the filtration process, the persistent homology barcodes recording the “birth” and “death” of
topological invariants can be generated along the spacial changing of radius on point-cloud dataset. The
machine learning feature vectors, as consequences, can be constructed from theses sets of filtration barcode
intervals.
The filtration parameter interval is discretized into bins, which can model the behavior of barcodes in
each bin [5]. Thus, these bins are packaged as features for advanced machine learning algorithms directly.
Then the number of persistence intervals is counted for each bin in order to record birth events and death
events. Three feature vectors (H0, H1, and H2) are generated for each topological barcode for the machine
learning method. Betti-0 (H0) barcode is obtained from the VR filtration and Betti-1 (H1), and Betti-2 (H2)
barcode is obtained from alpha complex filtration, where Betti-1 and Betti-2 are sparser and more stable
than Betti-0 barcodes. Thus, Betti-0 barcode is incorporated into CNN models, and Betti-1 and Betti-2
barcodes are for GBT training. Intuitively, features generated by binned barcode vectorization can reflect
the structure of the protein-protein complex and its biological and chemical properties, such as the strength
of atom bonds, van der Waals interactions. Meanwhile, taking the statistics of bar lengths, birth values,
and death values, such as maximum, minimum, mean, etc., can be set as features for the machine learning
process.
6.2.2 Machine learning models
To predict the binding affinity changes following mutations for PPIs is very challenging due to the com-
plex dataset and different 3D structures. To overcome this challenge, a hybrid machine learning algorithm
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which integrates a CNN and GBT to predict the binding affinity changes. The vectorized H0 barcode fea-
ture is converted into concise features by the CNN method. Then combine CNN-trained features and the
rest features as the full feature set to train a GBT module for a robust predictor with effective control of
overfitting.
CNN is considered as the most successful architectures as a class of deep neural networks. CNN is a
regularized case of a multilayer connected neural network. Each neuron is connected locally to the next
convolution layer neurons, and the weights are shared in different locations. In TopNetTree, CNN is an
intermediate model that applies vectorized H0 features into a higher-level abstract feature for the gradient
boosting tree method. Next, the GBT is an ensemble method that builds a powerful module for regression
and classification problems as weak learners. The method sums the weak learners to eliminate the overall
error based on the assumption that each learner is likely to make different mistakes. According to the
current prediction error on the training dataset, the ensemble method is built upon a decision tree structure.
GBT with topological features (TopGBT) is relatively robust against hyperparameter tuning and overfitting,
and is suitable for a moderate number of features. The current work uses the GBT package provided by
scikit-learn (v 0.23.0) [46].
Finally, TopNetTree follows the process (Fig. 10) that a supervised CNN model is trained for extracting
high-level features from H0 barcodes, where the PPI ∆∆G is a label. Then the flatten layer neural outputs
of CNN are ranked as their importance in a GBT model. Based on the importance, the whole features
consist of an ordered subset of CNN-trained features, high-dimensional topological barcodes, H1 and H2,
and auxiliary features for the final GBT model. As for the parameters, an optimal parameter setting with
the best result of the 10-fold evaluation is selected from the experiments of different parameter settings.
6.2.3 Cross-validation of TopNetTree
Table 5: Ten-fold cross-validation of the TopNetTree on the SKEMPI 2.0 dataset.
Rp τ RMSE (kcal/mol) Rp τ RMSE (kcal/mol)
Fold 1 (Train) 0.981 0.884 0.366 Fold 6 (Train) 0.983 0.904 0.353
Fold 1 (Test) 0.835 0.595 1.065 Fold 6 (Test) 0.836 0.594 1.064
Fold 2 (Train) 0.982 0.902 0.360 Fold 7 (Train) 0.983 0.904 0.356
Fold 2 (Test) 0.839 0.600 1.061 Fold 7 (Test) 0.838 0.594 1.060
Fold 3 (Train) 0.982 0.887 0.366 Fold 8 (Train) 0.979 0.878 0.392
Fold 3 (Test) 0.837 0.595 1.068 Fold 8 (Test) 0.840 0.596 1.061
Fold 4 (Train) 0.981 0.880 0.369 Fold 9 (Train) 0.982 0.902 0.362
Fold 4 (Test) 0.841 0.596 1.059 Fold 9 (Test) 0.838 0.596 1.069
Fold 5 (Train) 0.982 0.906 0.365 Fold 10 (Train) 0.982 0.886 0.367
Fold 5 (Test) 0.839 0.594 1.062 Fold 10 (Test) 0.835 0.596 1.064
Average (Train) 0.982 0.893 0.366
Average (Test) 0.838 0.596 1.063
The proposed TopNetTree method is trained on the SKEMPI 2.0 dataset [33], which has 4,169 variants in
319 different complexes. A set “S8338” with 8,338 variants was derived from SKEMPI 2.0 dataset by setting
the reverse mutation energy changes to the negative values of its original energy changes. To address the
reliability of the TopNetTree method, we did the tenfold cross-validation on the SKEMPI 2.0 dataset with
the averaged training accuracy, Pearson correlation coefficients Rp, Kendall’s τ , and the root mean square
error (RMSE), being 0.98, 0.89, and 0.37 kcal/mol. As shown in Table 5, these metrics are based on the
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average of ten ten-fold cross-validations, which indicate TopNetTree is well trained. The performance test
of tenfold cross-validation on dataset gives as Rp = 0.84, τ = 0.60, and RMSE = 1.06 kcal/mol, which is of
the same level of accuracy as the best in the literature [74].
6.3 Graph network analysis
Graph networks represent interactions between pairs of units in biomolecular systems. The quantify unique
characteristics of the networks can be measured for descriptions and comparisons of different networks.
Considering the protein-protein interactions as networks, each descriptor evaluates the network properties
and measures how proteins connect. For instance, a fixed domain of spike protein RBD and antibodies
forms a network, where residues from 320 to 518 on SARS-CoV and residue from 329 to 530 on SARS-CoV-
2 are considered in terms of Cα atoms. As aforementioned interaction subsets or similar subsets are defined
for Cα of each amino acid as following.
1. CAb(r): antibody Cα atoms within r A˚ of the binding site, where r =∞ is for all Cα atoms on antibody.
2. CAg(r): antigen Cα atoms within r A˚ of the binding site, where r =∞ is for all Cα atoms on antigen.
With these definitions, network descriptors are defined below.
FRI rigidity index The FRI rigidity index is a great tool to illustrate the elasticity between atoms for
molecular interaction prediction [43, 83]. The molecular rigidity index is defined as a summation of all the
atomic rigidity index µη,i as
Rη =
NAB∑
i=1
µη,i =
NAB∑
i=1
NAG∑
j=1
e−
( ‖ri−rj‖
η
)2
, (2)
where ri are atom positions, NAB and NAG are the numbers of atoms of antibody and antigen, respectively,
and r =∞ for all Cα atoms such that CAb(∞) and CAg(∞). TThe molecular rigidity index is used to describe
the behavior of the dynamics and elastostatics of the biomolecular elasticity where η controls the influence
range between atoms. In PPIs, the elasticity between antibody and antigen, especially long range impacts,
is studied by calculating the FRI index of the network consisting of Cα atoms.
Degree heterogeneity The degree heterogeneity is an index that evaluates the heterogeneity of a net-
work on different distribution [17]. The degree distribution ki is the number of i-th nodes that have ki
connections to other nodes. Therefore, the degree heterogeneity reflects the distributions of a network on
different impacts, which is defined as
ρ =
Ne∑
i=1
Ne∑
j=i+1
(k
−1/2
i − k−1/2j )2. (3)
Here, Ne represents for the number of edges. In our case, we study two networks consisting of all Cα atoms
in CAg(∞), that one network consists of Cα atoms from SARS-CoV RBD and SARS-CoV-2 RBD. The degree
heterogeneity illustrate the impacts of ACE2 or antibodies to these networks.
The rest descriptors are build on the network consist of Cα atoms from CAg(∞) and CAb(10).
Edge density The edge density is defined as
d =
2Ne
Nv(Nv − 1) , (4)
where Ne is the number of edges and Nv is the number of vertices for Cα atoms from CAg(∞) and CAb(10).
The edge density is also called the average degree centrality. For a complete network in which each every
pair of network vertices is connected, the edge density is equal to one. A non-complete network has an edge
21
density smaller than one. With the same number of residues in RBD for each PPI, a higher edge density
stands for a firmly connection between RBD and ACE2 or antibodies.
Average path length The characteristic path length studies the typical separation between two vertices
in the network. It was used to study infectious diseases spread in so called “small-world” networks [76].
The shortest path distance d(i, j) is defined as the shortest path between the corresponding pairs of vertex i
and j. In protein-protein interactions, the path length between two atoms reflects how ACE2 or antibodies
connect to RBD. The average path length is defined as
〈L〉 = 1
Nv(Nv − 1)
Nv∑
i=1
Nv∑
j=i+1
d(i, j), (5)
for Cα atoms from CAg(∞) and CAb(10). Here, Nv represents for the number of vertices.
Average betweenness centrality The concept of betweenness centrality illustrates communications in a
network [24]. The betweenness centrality of a vertex vk is given as
Cb(vk) =
Nv∑
i=1
Nv∑
j=i+1
gij(vk)/gij (6)
and the average betweenness centrality is given as
〈Cb〉 = 1
Nv
Nv∑
k=1
Cb(vk), (7)
where gij(vk) is defined as the number of geodesics linking between vertex vi and vj that passes vk, and gij
considers all the paths between vi and vj . And Nv means the number of vertices.
Average eigencentrality The eigenvector centrality are the elements of the eigenvector Vmax with respect
to the largest eigenvalue of the adjacency matrix A [2]. It describes the probability of starting and returning
at the same point for infinite length walks. Thus the average eigenvector centrality is,
〈Ce〉 = 1
Nv
Nv∑
i=1
ei, (8)
where ei are elements of Vmax. It stands for the average impact spread of vertices beyond its neighborhood
for an infinite walk.
Average subgraph centrality The following descriptors are built on the exponential of the adjacency
matrix, E = eA. The average subgraph centrality is defined as
〈Cs〉 = 1
Nv
Nv∑
k=1
E(k, k), (9)
which indicates the vertex participating in all subgraphs of the graphs [18, 21]. Here, E(k, k) means the
element located at the k-th row and k-th column. Subgraph centrality is the summation of weighted closed
walks of all lengths starting and ending at same node. The long path length has a small contribution.
Average communicability Finally, the last two descriptors are average communicability given as
〈M〉 = 2
Nv(Nv − 1)
Nv∑
i=1
Nv∑
j=i+1
E(i, j), (10)
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and average communicability angle given as
〈Θ〉 = 2
Nv(Nv − 1)
Nv∑
i=1
Nv∑
j=i+1
θ(i, j), (11)
where θ(i, j) = arccos
(
E(i,j)√
E(i,i),E(j,j)
)
and E is the exponential of the adjacency matrix. The average com-
municability measures how much two vertices can communicate by using all the possible paths in the
network, where the shorter path has more weight [19]. The average communicability angle evaluates the
efficiency of two vertices passing impacts to each other in the network with all possible paths [18, 20].
Conclusion
Currently, developing effective therapies for combating Coronavirus disease 2019 (COVID-19) caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes a vital task for human health and
the world economy. Although designing new anti-SARS-CoV-2 drugs is of paramount importance, tra-
ditional drug discovery might take many years. Effective vaccines typically require more than a year to
develop. Therefore, a more efficient strategy in fighting against COVID-19 is to look for antibody therapies,
which is a relatively easier technique compared to the development of small-molecular drugs or vaccines.
Seeking possible antibody drugs has attracted increasing attention in recent months. Moreover, comple-
mentarity determining regions (CDRs) which located in the tip of the antibody, determine the specificity
of antibodies and make the antibody therapies a promising way to fight against COVID-19. We analyze
the structure, function, and therapeutic potential of seven SARS-CoV-2 neutralizing antibody candidates
that have three-dimensional (3D) structures available in the Protein Data Bank. In a comparative study,
we also review five antibody structures associated with SARS-CoV and angiotensin-converting enzyme 2
(ACE2) complexes with both SARS-CoV-2 and SARS-CoV spike proteins. The multiple order of magnitude
discrepancies in reported experimental binding affinities motivates us to carry a systematic computational
analysis of the aforementioned fourteen complexes. Using computational topology, machine learning, and
wide class network models, we put all of the complexes in an equal footing to evaluate binding and in-
teractions. Additionally, we have predicted binding affinities of five SARS-CoV antibodies when they are
used as SARS-COV-2 therapies. Finally, we summarize all of the currently ongoing clinical antibody trails
for SARS-CoV-2, which have many targets, including the S protein. In a nutshell, we provide a review of
existing antibody therapies for COVID-19 and introduce many theoretical models to rank the potency and
analyze the properties of antibodies.
Supporting Material
Supporting Materials are available for S1: Network analysis of antibody-antigen complexes and S2: Binding
affinity changes following mutations.
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